Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine with anticonvulsant properties. It is used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures in patients 2 years of age and older with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initiation:** Typically 5 mg twice daily.
* **Maintenance:** Titrate by 5-10 mg per day every week based on clinical response and tolerability.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day) for patients weighing >30 kg.
* **Maximum Daily Dose:** 10 mg twice daily (20 mg/day) for patients weighing ≤30 kg.
## Pediatric Dosing (2 years and older)
* **Initiation:** Typically 2.5 mg twice daily.
* **Maintenance:** Titrate by 2.5-5 mg per day every week based on clinical response and tolerability.
* **Maximum Daily Dose:** 10 mg twice daily (20 mg/day) for patients weighing ≤30 kg.
* **Maximum Daily Dose:** 20 mg twice daily (40 mg/day) for patients weighing >30 kg.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. No specific dose adjustments provided, but reduced dosage may be warranted.
* **Renal Impairment:** Use with caution. No specific dose adjustments provided, but reduced dosage may be warranted.
* **Concomitant Medications:** Reduce clobazam dose if co-administered with strong CYP2C19 inhibitors (e.g., fluconazole). Consider dose adjustments if co-administered with strong CYP3A4 inducers or inhibitors.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, decreased appetite, constipation, aggression, irritability, upper respiratory tract infection, pyrexia, vomiting, gait disturbance, fatigue, drooling.
* **Serious:** Suicidal ideation and behavior, severe dermatologic reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms, paradoxical reactions.
## Key Drug Interactions
* **CYP2C19 Inhibitors (e.g., fluconazole, omeprazole):** Increase clobazam concentrations. Consider reducing clobazam dose.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** Increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., rifampin, carbamazepine, phenytoin):** Decrease clobazam concentrations.
* **CNS Depressants (e.g., opioids, alcohol, other sedatives):** Additive CNS depressant effects.
## Monitoring
* **Clinical:** Monitor for seizure frequency and control, and for signs of suicidal ideation or behavior. Assess for somnolence and cognitive impairment.
* **Laboratory:** Routine laboratory monitoring is not typically required.
* **Withdrawal:** Monitor for signs and symptoms of withdrawal if discontinuing therapy, especially after prolonged use. Taper dosage gradually.
## Clinical Pearls
* Clobazam has a longer half-life compared to other benzodiazepines, which may allow for less frequent dosing.
* Due to the risk of serious dermatologic reactions, patients should be advised to seek medical attention immediately if they develop a rash.
* Clobazam can cause dose-dependent cognitive and motor impairment.
* Abrupt discontinuation can lead to withdrawal symptoms. Gradual tapering is recommended.
***
*This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete details before making any clinical decisions.*
